Abstract
This editorial refers to ‘The ‘obesity paradox’ in atrial fibrillation: observations from the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) trial’†, by R.K. Sandhu et al., on page 2869.
Funding Information
  • Robert J. Craig Lectureship from the University of Adelaide
  • Robert J. Craig Scholarship from the University of Adelaide
  • Practitioner Fellowships from the National Health and Medical Research Council of Australia
  • National Heart Foundation of Australia

This publication has 14 references indexed in Scilit: